541 related articles for article (PubMed ID: 24462284)
1. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
[TBL] [Abstract][Full Text] [Related]
2. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
[TBL] [Abstract][Full Text] [Related]
3. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
Di Fabio F; Aston W; Mohamed F; Chandrakumaran K; Cecil T; Moran B
Colorectal Dis; 2015 Aug; 17(8):698-703. PubMed ID: 25704482
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
[TBL] [Abstract][Full Text] [Related]
7. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
[TBL] [Abstract][Full Text] [Related]
8. Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.
Di Fabio F; Mehta A; Chandrakumaran K; Mohamed F; Cecil T; Moran B
Ann Surg Oncol; 2016 Dec; 23(13):4316-4321. PubMed ID: 27380645
[TBL] [Abstract][Full Text] [Related]
9. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.
van Ruth S; Hart AA; Bonfrer JM; Verwaal VJ; Zoetmulder FA
Ann Surg Oncol; 2002 Dec; 9(10):961-7. PubMed ID: 12464587
[TBL] [Abstract][Full Text] [Related]
11. The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin.
Rangarajan K; Chandrakumaran K; Dayal S; Mohamed F; Moran BJ; Cecil TD
Int J Hyperthermia; 2018 Aug; 34(5):559-563. PubMed ID: 29063804
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.
Solomon D; Bekhor E; Leigh N; Maniar YM; Totin L; Hofstedt M; Aycart SN; Carr J; Ballentine S; Magge DR; Golas BJ; Pai RK; Polydorides AD; Bartlett DL; Labow DM; Choudry HA; Sarpel U
Ann Surg Oncol; 2020 Jan; 27(1):147-153. PubMed ID: 31385130
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
15. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
[TBL] [Abstract][Full Text] [Related]
17. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
[No Abstract] [Full Text] [Related]
18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
[TBL] [Abstract][Full Text] [Related]
19. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.
Ansari N; Chandrakumaran K; Dayal S; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2016 Jul; 42(7):1035-41. PubMed ID: 27132072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]